Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Immunotherapy Continues to Impress in GU Malignancies

November 7th 2017

Andrea Apolo, MD, discusses the combination of cabozantinib plus nivolumab and ipilimumab, as well as the latest data on avelumab in urothelial carcinoma.

Nivolumab Sustains Survival Benefit in RCC at 3 Years

November 7th 2017

Nivolumab reduced the risk of death by 26% compared with everolimus in patients with previously treated advanced renal cell carcinoma.

NICE Recommends Frontline Atezolizumab for Advanced Urothelial Cancer

November 2nd 2017

The UK’s National Institute for Health and Care Excellence is recommending the use of atezolizumab for treatment-naïve patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-based therapy.

Dr. Armstrong Discusses Hereditary Prostate Cancer

November 1st 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

Dr. Geynisman on Patient Preferences for Treatment of RCC

November 1st 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

Dr. Friedlander on Checkpoint Inhibitors in Second-Line Bladder Cancer Treatment

October 31st 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in second-line bladder cancer treatment.

Research Underway to Cure Locally Advanced Urothelial Carcinoma

October 31st 2017

Elizabeth Plimack, MD, discusses the management of locally advanced urothelial carcinoma and the ongoing trials that are investigating treatments for this patient population.

Dr. Zibelman on Combinations of Immunotherapy for RCC

October 30th 2017

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy combinations in the treatment of patients with renal cell carcinoma (RCC).

Improved Patient Selection Needed to Optimize Expanding Options in Bladder Cancer

October 27th 2017

Jean Hoffman-Censits, MD, discusses ever-changing bladder cancer field, ongoing combination trials that are showing early promise, and the unmet need of patient selection for novel therapies.

Dr. Hoffman-Censits Discusses the Future Treatment of Bladder Cancer

October 26th 2017

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Dr. Uzzo Discusses the Role of Surgery in Kidney Cancer

October 26th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses the role of surgery in kidney cancer.

Dr. Geynisman Discusses Immunotherapy in RCC

October 23rd 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma.

NICE Rejects Treatments for Bladder and Thyroid Cancer

October 21st 2017

The UK’s National Institute for Health and Care Excellence has issued guidelines recommending against nivolumab (Opdivo), lenvatinib (Lenvima), and sorafenib (Nexavar).

Steps Being Taken to Turn mRCC Into a Chronic Disease

October 21st 2017

Daniel M. Geynisman, MD, discusses remaining challenges in the landscape of RCC, despite progress with systemic therapies and the pivotal ongoing studies combining immunotherapy and targeted therapy.

Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate Cancer

October 20th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

Dr. Harrison on the Possibility of Nivolumab Plus Ipilimumab Becoming the New IL-2

October 20th 2017

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses the possibility of nivolumab (Opdivo) plus ipilimumab (Yervoy) becoming the new interleukin-2 (IL-2).

Dr. Hoffman-Censits Discusses Immunotherapy in Bladder Cancer

October 19th 2017

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.

Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma

October 18th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.

Dr. Bosse on the Quality of Life With VEGF Plus Radium-223

October 18th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

FDA Grants Priority Review to Frontline Cabozantinib in RCC

October 16th 2017

The FDA has granted a priority review to a supplemental new drug application for cabozantinib (Cabometyx) for previously untreated patients with advanced renal cell carcinoma.